ArticleBMJ neurology open2021

Sodium selenate as a disease-modifying treatment for mild-moderate Alzheimer's disease: an open-label extension study.

Lucy Vivash et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.